2019 Preliminary Program

PRELIMINARY PROGRAM 

Working titles/topics shown. Final titles and speakers will follow


EDUCATIONAL SESSIONS - Supported in part by an educational grant from Susan G. Komen(R)
Tuesday, December 10, 2019

Most of the presentations at SABCS focus on the latest clinical and basic research results relating to breast cancer. By contrast, educational sessions are designed to inform and update those interested in a review on a particular topic. Although these sessions may include new specific research findings, their primary intent is to offer summaries of existing knowledge, and to provide background for some of the active areas which will be discussed in the rest of the meeting.

Multidisciplinary Approach to Optimizing Local Regional Therapy in Hormone Receptor Positive Breast Cancer
Moderator: Armando Giuliano, MD
Cedars-Sinai Medical Center
Los Angeles, CA

Neoadjuvant therapy for hormone receptor positive breast cancer: Challenges and advances 
Otto Metzger, MD
Dana-Farber Cancer Institute,
Boston, MA

Surgical management of the upfront surgery patient
Melissa L. Pilewskie, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Local regional therapy considerations after preoperative therapy in hormone receptor positive breast cancer
Tari Ann King, MD
Dana-Farber Cancer Institute
Brigham and Women's Cancer Center
Boston, MA

Tailoring Adjuvant Therapies Based on Neoadjuvant Response
Moderator: Charles E. Geyer, MD
Virginia Commonwealth University
Massey Cancer Center
Richmond, VA

The biology and plasticity of residual disease
Charles M. Perou, PhD
University of North Carolina
Chapel Hill, NC

Neoadjuvant treatment: Tailoring response by subtype
Jenny C. Chang, MD
Houston Methodist Hospital
Houston, TX

Local regional treatment in patients who achieve pathologic complete response
Julia White, MD
The Ohio State University
Columbus, OH

Targeted Treatment Beyond PARP1 Inhibition
Moderator: Alexander Bishop, DPhil
Greehey Children's Cancer Research Institute
UT Health San Antonio
San Antonio, TX

Clinical indications of PARP1 inhibitors and other targets
Melinda L. Telli, MD
Stanford University Medical Center
Stanford, CA

Novel DNA repair targets for breast cancer
Thomas Helleday, PhD
University of Sheffield
Sheffield, UNITED KINGDOM

Clinically relevant biomarkers of PARP1 inhibitor resistance and indicators of targeted combinatorial treatments 
Violeta Serra, PhD
Vall d'Hebron Institute of Oncology
Barcelona, SPAIN

Implementation of Genetic Testing in Breast Cancer Patients
Moderator: Virginia G. Kaklamani, MD
UT Health San Antonio
San Antonio, TX

Genetic testing for hereditary breast cancer: Who should be tested?  
Nadine Tung, MD
Beth Israel Deaconess Medical Center
Boston, MA

Alternativepractical models for genetic services in the era of increased demand 
Banu Arun, MD
University of Texas MD Anderson Cancer Center
Houston, TX

Breast cancer genetic testing: moving from cancer risk assessment to therapeutic biomarker
Judith Balmaña, MD, PhD
Vall d'Hebron University Hospital
Barcelona, SPAIN

Acquired Endocrine Therapy Resistance Beyond ESR1 Mutations
Moderator: Carlos L. Arteaga, MD
UT Southwestern Medical Center
Simmons Comprehensive Cancer Center
Dallas, TX

Adaptive resistance to hormonal therapy
Suzanne A.W. Fuqua, PhD
Baylor College of Medicine
Houston, TX

Exploiting single cell transcriptome analyses to track adaptation to endocrine therapies
Luca Magnani, PhD
Imperial College London 
London, UNITED KINGDOM

The genomic landscape of endocrine-resistant metastatic breast cancer
Pedram Razavi, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Breast Cancer Prevention
Moderator: Judy E. Garber, MD, MPH
Dana-Farber Cancer Institute
Boston, MA

Targeted approach to breast cancer surveillance in high risk women: Update of the newest technologies and how to use them
Maxine S. Jochelson, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Managementof high risk women: considering the time-frame
Seema A. Khan, MD
Northwestern University
Chicago, IL

Low dose tamoxifen and other approaches to improve chemoprevention uptake  
Andrea De Censi, MD
E.O. Ospedali Galliera 
Genova, ITALY

Evolving Opportunities to Personalize Radiation Decisions
Moderator: Reshma Jagsi, MD, DPhil
University of Michigan
Ann Arbor, MI

Guiding decisions to omit radiotherapy after breast-conserving surgery for DCIS. Can genomic biomarkers help?   
Eileen Rakovitch, MD, MSc, FRCPC
Sunnybrook Health Sciences Centre
Toronto, CANADA

Guiding decisions to omit radiation after breast conserving surgery for invasive breast cancer
Corey Speers MD, PhD
University of Michigan
Ann Arbor, MI

Guiding selection of RT approach after lumpectomy
Simona Shaitelman, MD
University of Texas MD Anderson Cancer Center 
Houston, TX

Conversations on Tough Topics Surrounding Cancer Care
Moderator: Susan Rafte
Community Advocate, Baylor College of Medicine Breast Center
Houston, TX

Progression of disease and end of life: How to break bad news
Eric P. Winer, MD
Dana-Farber Cancer Institute
Boston, MA

Challenging conversations: The toll on healthcare providers
Sharon H. Giordano, MD, MPH, FASCO
University of Texas MD Anderson Cancer Center
Houston, TX

The financial costs and burden of breast cancer care
Rachel A. Greenup, MD, MPH
Duke Cancer Institute
Durham, NC

Panel Discussion

Thelma P. Brown
University of Alabama at Birmingham
Birmingham, AL

Katherine O'Brien
Metastatic Breast Cancer Network
New York, NY

Immunotherapy For Triple –Negative Breast Cancer
Moderator: Sylvia Adams, MD
NYU Langone Health
New York, NY

The emergingrole of immunotherapy for the treatment of early and advanced breast cancer
Rita Nanda, MD
University of Chicago
Chicago, IL

Detecting and managing IO related toxicities wisely
Peter Schmid, MD, PhD
Barts Cancer Institute
London, UNITED KINGDOM

Assessment of PD-L1/PD-1: If, when, why and how
David L. Rimm, MD, PhD
Yale University School of Medicine
New Haven, CT

Breast Cell Fate Control and Plasticity
Moderator: Yi Li, PhD
Baylor College of Medicine
Houston, TX

Cell fate and plasticity in the mammary gland
Cédric Blanpain, MD, PhD
Universite Libre de Bruxelles
Bruxelles, BELGIUM

Deconstructing breast cancer from a developmental perspective
Geoffrey Wahl, PhD
Salk Institute for Biological Studies
La Jolla, CA

Cell fate plasticity during breast cancer development -where is the translational utility?
Christina Scheel, MD
Helmholtz Center Munich
Institute of Stem Cell Research
Neuherberg, GERMANY

Endocrine Therapy 2020
Moderator: Mothaffar Rimawi, MD
Baylor College of Medicine
Houston, TX

Adjuvant endocrine therapy in 2020: It's complicated
Angelo Di Leo, MD, PhD
Hospital of Prato 
Prato, ITALY

Endocrine therapy beyond 2020 (metastatic, new agents)
Erica L. Mayer, MD, MPH
Dana-Farber Cancer Institute
Harvard Medical School 
Boston, MA

Everything comes with a price (toxicity)
Dawn Hershman, MD
Columbia University Medical Center
New York Presbyterian Hospital
New York, NY 

Discussing Risk in the Context of GEP Testing
Moderator: Lesley Fallowfield, BSc, DPhil
Sussex Health Outcomes Research & Education in Cancer (SHORE-C)
Brighton & Sussex Medical School
Brighton, UNITED KINGDOM

TBA
Lesley Fallowfield, BSc, DPhil
Sussex Health Outcomes Research & Education in Cancer (SHORE-C)
Brighton & Sussex Medical School
Brighton, UNITED KINGDOM

TBA
Valerie Ann Jenkins, DPhil, BSc
Sussex Health Outcomes Research & Education in Cancer (SHORE-C)
Brighton & Sussex Medical School
Brighton, UNITED KINGDOM

Top

 



 

William L. McGuire Memorial Lecture

TBA
Joseph Sparano, MD
Montefiore Medical Center
Bronx, NY

AACR Distinguished Lectureship in Breast Cancer Research

AACR Outstanding Investigator Award for Breast Cancer Research, funded by the Breast Cancer Research Foundation

Susan G. Komen® Brinker Awards

Top



Metastatic Breast Cancer Oligo Too Many: A Role For Ablative Therapy?
Ralph R. Weichselbaum, MD
University of Chicago
Chicago, IL

Stromal cells and matrixremodeling as essential regulators of the tumor microenvironment 
Ellen Puré, PhD
University of Pennsylvania
Philadelphia, PA

Top



Future of Immuno-oncology in Breast Cancer
Co-Moderator: Jenny C. Chang, MD
Houston Methodist Hospital
Houston, TX

Co-Moderator: Helen Heslop, MB ChB, MD, DSc
Baylor College of Medicine
Houston, TX

Immunotherapy in breast cancer: enhancing response to checkpoint blockade
Elizabeth A. Mittendorf, MD, PhD
Dana-Farber Cancer Institute
Brigham and Women's Cancer Center
Boston, MA

Engineering next-genT cell based immunotherapies for breast cancer
Christopher A. Klebanoff, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Targeting the Cell Cycle Kinase CDK 4/6 and Beyond
Moderator: Angela DeMichele, MD, MSCE
Abramson Cancer Center
University of Pennsylvania
Philadelphia, PA

Mechanisms of resistance to CDK4/6inhibitors and new therapeutic approaches
Sarat Chandarlapaty, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Targeting the cell cycle - Beyond CDK4/6 inhibition
Rinath Jeselsohn, MD
Dana-Farber Cancer Institute
Boston, MA

Top

 

 

 

 

 


Saturday, December 14, 2019

Moderator: C. Kent Osborne, MD
Baylor College of Medicine
Dan L. Duncan Comprehensive Cancer Center
Houston, TX

Basic science
Alana L. Welm, PhD
University of Utah
Huntsman Cancer Institute
Salt Lake City, UT

Translational research
Geoffrey Lindeman, MB BS, FRACP, PhD
The Walter & Eliza Hall Institute of Medical Research
Parkville, AUSTRALIA

Early breast cancer   
Masakazu Toi, MD, PhD
Kyoto University
Kyoto, JAPAN

Metastatic breast cancer
Sara Hurvitz, MD
University of California Los Angeles
Los Angeles, CA

Top
 



RNA Rewiring in Breast Cancer Progression
Moderator: Chonghui Cheng, MD, PhD
Baylor College of Medicine
Houston, TX

Genome regulation by long noncoding RNA's
Howard Chang, MD, PhD
Stanford University
Stanford, CA

RNA methylation in cancer progression
Chuan He, PhD
University of Chicago 
Chicago, IL

Top



The Communal Road to Metastasis: CTC Clusters
Moderator: Rachel Schiff, PhD
Baylor College of Medicine
Lester & Sue Smith Breast Center
Houston, TX

CTC clusters, cancer stemness, and new treatment strategies 
Huiping Liu, MD, PhD
Northwestern University
Chicago, IL

Biology, vulnerabilities and clinical implications of CTC clusters
Nicola Aceto, PhD
University of Basel
Basel, SWITZERLAND

Proteogenomics of Breast Cancer, From Discovery to Precision Medicine
Moderator: Matthew J. Ellis, MB, BChir, BSc., PhD, FRCP
Baylor College of Medicine
Lester & Sue Smith Breast Center
Houston, TX

Advanced enabling technologies for cancer proteomics 
Tao Liu, PhD
Pacific Northwest National Laboratory
Richland, WA 

Clinical proteomics tumor analysis consortium breast cancer marker studies 
Michael Gillette, MD, PhD
Broad Institute
Cambridge, MA 

Proteogenomics and clinical translation
Matthew J. Ellis, MB, BChir, BSc., PhD, FRCP
Baylor College of Medicine
Houston, TX

Top



Frontiers in HER2 Positive Breast Cancer
Moderator: Sibylle Loibl MD
German Breast Group
Frankfurt, GERMANY

Heterogeneity of HER2+ breast cancer
Andrea L. Richardson, MD, PhD
Johns Hopkins Medicine
Baltimore, MD

New agents for HER2+ treatment
Shanu Modi, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Brain metastases - clinical dilemmas and scientific challenges
Nancy U. Lin, MD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA

Top



Molecular Biology in Breast Oncology
Moderator: Carlos L. Arteaga, MD
UT Southwestern Medical Center
Simmons Comprehensive Cancer Center
Dallas, TX

Antibody-drug conjugates in cancer: Principles for synthesis and preclinical development
Gail Lewis Phillips
Genentech, Inc.
South San Francisco, CA

Defining a cancer dependency map
William C. Hahn, MD, PhD
Dana-Farber Cancer Institute
Boston, MA

Approaches to targeting the anti-apoptotic machinery in breast cancer
Geoffrey Lindeman, MB BS, FRACP, PhD
The Walter & Eliza Hall Institute of Medical Research
Parkville, AUSTRALIA

Novel target discovery by longitudinal deep spatial & molecular analysis of breast cancers
Joe Gray, PhD
Oregon Health & Science University
Portland, OR

Developing Novel Therapeutics in the Metastatic Setting
Moderator: Virginia G. Kaklamani, MD
UT Health San Antonio
San Antonio, TX

Window versus neoadjuvant trial - choose wisely
Alastair M. Thompson, BSc (Hons), MB ChB, MD, FRCSEd
Baylor College of Medicine
Houston, TX

Therapeutic development in the era of precision medicine: Paradigm shift from maximum tolerated dose (MTD) to optimal biological dose (OBD)
Aditya Bardia, MD, MPH
Massachusetts General Hospital
Harvard Medical School
Boston, MA

Design and analysis of window and neoadjuvant trials
Meredith Regan, ScD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA

How to talk to patients about participating in clinical trials
Patricia Spears, BSc
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, NC

 

Top



                                                                                                                       

Moderator: Mothaffar Rimawi, MD
Baylor College of Medicine
Houston, TX                                                                                                                           



CAREER DEVELOPMENT FORUMNETWORKING SESSION FOR YOUNG INVESTIGATORS

                                                                                                                       

The session is open to early-career scientists, defined as graduate students, postdoctoral or clinical fellows, or medical students and residents, who are registered attendees of the 2019 SABCS. Space in the workshop is limited. Preregistration is not required.                                                                                                                             




  

Mastectomy should not be offered to patients who are breast conservation candidates when modern radiotherapy is available
Chairman: Richard Crownover, MD, PhD
UT Health San Antonio
San Antonio, TX

             For
             Lawrence B. Marks, MD, FASTRO
             University of North Carolina at Chapel Hill School of Medicine
             Chapel Hill, NC

                                                                                                                                                                                    

             Against
             Alastair M. Thompson, ALCM, BSc(Hons), MBChB, MD,
             FRCSEd(Gen)
             Baylor College of Medicine
             Houston, TX

 

Friday, December 13, 2019: 


        Moderator: Ruth O'Regan, MD
        University of Wisconsin
        Carbone Cancer Center
        Madison, WI

        Panel Members

        Joseph Sparano, MD
        Montefiore Medical Center
        Albert Einstein College of Medicine
        Bronx, NY

        Debra A. Patt, MD, MPH
        Texas Oncology
        Austin, TX

        Nadia Harbeck, MD, PhD
        Ludwig Maximilian University of Munich
        Munich, GERMANY

        Barbara Segarra-Vázquez, MT, DHSc
        University of Puerto Rico
        San Juan, PR

        E. Shelley Hwang, MD, MPH
        Duke University
        Durham, NC Top


PRELIMINARY SCHEDULE


Hours subject to change



 

Monday, December 9  Registration  12:00 PM - 5:00 PM 
Tuesday, December 10  Registration  8:00 AM - 7:00 PM ;
  Program (Workshops and Educational Sessions)  11:45 AM - 7:00 PM 
Wednesday, December 11  Registration  7:00 AM - 5:15 PM 
  Program (Main Program begins)  8:00 AM - 7:00 PM 
  Exhibits  10:45 AM - 5:00 PM 
Thursday, December 12  Registration  6:45 AM - 5:15 PM 
  Program  7:00 AM - 7:00 PM 
  Exhibits  10:45 AM - 5:00 PM 
Friday, December 13  Registration  6:45 AM - 5:15 PM 
  Program  7:00 AM - 7:30 PM 
  Exhibits  10:45 AM - 5:00 PM 
Saturday, December 14  Registration  6:45 AM - 9:00 AM 
  Program  7:00 AM - 11:00 AM 

Top